VolitionRx’s (VNRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a report published on Wednesday,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the stock. StockNews.com started coverage on shares of VolitionRx in a report on Tuesday. They set a “sell” rating for the company. HC Wainwright began coverage on shares of VolitionRx in a research note on Tuesday, April 8th. They issued a “buy” rating and a $2.50 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.33.

VolitionRx Stock Down 2.6 %

NYSE VNRX opened at $0.48 on Wednesday. VolitionRx has a twelve month low of $0.42 and a twelve month high of $0.91. The business has a 50-day moving average price of $0.53 and a 200-day moving average price of $0.60. The firm has a market cap of $47.87 million, a price-to-earnings ratio of -1.32 and a beta of 1.15.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds acquired 181,818 shares of VolitionRx stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of $0.55 per share, with a total value of $99,999.90. Following the completion of the purchase, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. The trade was a 8.59 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 12.80% of the stock is owned by insiders.

Hedge Funds Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Two Sigma Securities LLC bought a new stake in VolitionRx in the fourth quarter worth $29,000. Millennium Management LLC purchased a new position in VolitionRx during the 4th quarter worth $36,000. Northern Trust Corp raised its holdings in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. lifted its holdings in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.